Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04EJG
|
|||
| Drug Name |
SHR-1314
|
|||
| Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 1/2 | [1] | |
| Company |
Jiangsu HengRui Medicine Shanghai, China
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-17 (IL17) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL23-mediated signaling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Allograft Rejection | ||||
| IL17 signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.